S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion
ConditionTransfusion Related Complication
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-35
SponsorJames Reynolds
About this trial
The Purpose of the study is to test the hypothesis that administration of an S-nitrosylating (SNO) agent can improve tissue oxygenation during transfusion of packed red blood cells (RBCs).
Eligibility criteria
Qualifiers
Hemoglobin > 12 g/dl
Healthy, non-pregnant adults with no pre-existing blood disorders or disease states that impact oxygen delivery.
Disqualifiers
Individuals who are pregnant, breastfeeding, or are unwilling to avoid pregnancy during the study.
Individuals with an anatomic anomaly that would increase the risks associated with placement of the vascular catheters.
Individuals who report chronic diseases requiring medication of the heart, lungs, kidney, liver, etc or afflicted with any acute or chronic pathology that in the opinion of the screening physician makes them unsuitable for study.
Individuals with a recent history of antibiotic therapy (check for underlying cause).
Trial design
Treatments tested in this trial
- SNO
- Normal Saline
- Red Blood Cell
Treatment groups
35 Participants
are divided into 2 treatment groupsSponsors and collaborators
James Reynolds
Lead sponsor
Case Western Reserve University
Sponsor institution
Case Western Reserve University
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov